Danaher: Solid Core Performance and Bioprocessing Upside Support Buy Rating into 2026

Danaher, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tycho Peterson from Jefferies maintained a Buy rating on the stock and has a $265.00 price target.

Tycho Peterson has given his Buy rating due to a combination of factors that indicate a constructive outlook for Danaher’s growth and profitability into 2026. The company’s fourth-quarter results were solid versus expectations, with particular strength in bioprocessing consumables and key diagnostics franchises, underscoring the resilience of its core healthcare and life sciences portfolio. Management’s 2026 guidance, calling for mid‑single‑digit core growth and high‑single‑digit EPS expansion, is viewed as achievable, with a deliberate under‑promise/over‑deliver setup supported by easing comparisons in the back half of the year and the timing of cost savings.

Peterson also highlights bioprocessing and life sciences as key upside levers that could push growth and earnings above the baseline outlook. In bioprocessing, stabilizing equipment demand, improving order trends, and healthy consumables tied to biologics, biosimilars, and mAbs provide a clear path to high‑single‑digit growth, with additional optionality from greenfield and reshoring projects. In life sciences, any recovery in U.S. academic/government spending, biotech funding translating into orders, and a rebound in China research could lift segment performance above current assumptions. Coupled with a more supportive M&A environment and a valuation that already reflects conservative expectations, these factors collectively underpin Peterson’s Buy recommendation on Danaher.

Peterson covers the Healthcare sector, focusing on stocks such as Merck & Company, Qiagen, and Danaher. According to TipRanks, Peterson has an average return of 9.9% and a 59.09% success rate on recommended stocks.